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S U M M A R Y
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogen of public health
importance. The prevalence of MRSA and its antimicrobial resistance pattern, as well as SCCmec and
spa types, remain unclear both in the community and in the hospitals of the western region of Iran.
Methods: One hundred MRSA isolates were collected from different hospitals in the west of Iran during
2010–2011. Antimicrobial susceptibility testing to 15 antimicrobial agents was carried out by disk agar
diffusion (DAD) method in accordance with the Clinical and Laboratory Standards Institute guidelines.
Vancomycin minimum inhibitory concentrations (MICs) were evaluated by a broth microdilution
method. The Etest was used for the detection of highly gentamicin-resistant MRSA. A combination of
single and multiplex PCR was used for the detection of different resistance genes, including beta-
lactamase, aminoglycoside modifying enzymes (AMEs), and macrolide–lincosamine, and for SCCmec
typing of MRSA isolates. Genotyping of MRSA isolates was performed via spa typing.
Results: All tested isolates were susceptible to quinupristin–dalfopristin, linezolid, and vancomycin, but
were resistant to penicillin (100%), erythromycin (50%), clindamycin (27%), and gentamicin (18%). MIC50
and MIC90 was 256 mg/ml among gentamicin-resistant MRSA. The most prevalent AME genes among
aminoglycoside-resistant isolates were aac(60)-1e-aph(200)-1a (77.8%), aph(30)-IIIa (38.9%), and ant(40)-1a
(27.8%). Nearly all tetracycline- and erythromycin-resistant MRSA had ermA and/or ermC but not ermB.
Five SCCmec types and subtypes, 13 spa types, and four BURP groups (A–D) were identiﬁed. SCCmec types
III (45%) and IVc (24%), spa type t701 (30%), and new spa type t12311 (15%) were the most prevalent
among MRSA isolates.
Conclusions: This study showed the emergence of MRSA with SCCmec type III and with spa types t12311,
t10740, t1234, t1991, and t2651 with different phenotypic and genotypic antimicrobial resistance in the
west of Iran. We found different SCCmec and spa types distributed among nosocomial and non-
nosocomial MRSA in the west of Iran.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Staphylococcus aureus is a major cause of many infections in
healthcare and community settings, and due to resistance to most
classes of antimicrobial agents, therapeutic options for these
infections are reduced dramatically.1 The emergence of methicil-
lin-resistant S. aureus (MRSA) among both hospital-acquired (HA)
and community-acquired (CA) infections highlights this species as
a potential pathogen that is able to adapt under the pressure of
antimicrobial agents.
Different classes of antibiotics have been applied to treat
staphylococcal infections, including beta-lactams, glycopeptides,
lipopeptide, oxazolidones, aminoglycosides, macrolides, tetracy-
clines, ﬂuoroquinolones, etc. Resistance against a wide variety of
antimicrobial agents, even to vancomycin – the drug of choice for
staphylococcal infections – is another important factor concerning
the treatment of infections caused by this bacterium. Strains
resistant to penicillin secrete beta-lactamase (through the blaZ
gene), which hydrolyzes the beta-lactam ring of antibiotics.
Resistance to methicillin is encoded by the staphylococcal cassette
chromosome mec (SCCmec) element, composed of the mec gene
complex, and the ccr (cassette chromosome recombinase) gene
complex, encoding the recombinase gene. Several molecular typing
methods such as SCCmec typing, spa typing, pulsed-ﬁeld gel
electrophoresis (PFGE), and multilocus sequence typing (MLST)
are used for the epidemiological characterization of MRSA isolates.2,3
SCCmec elements have been classiﬁed into 11 major types (I–
XI), some of which are differentiated further into subtypes. SCCmec
types I, II, and III have been associated more frequently with
hospital-acquired MRSA (HA-MRSA), and types IV and V have been
associated more frequently with community-acquired MRSA (CA-
MRSA).4–6
CA-MRSA differs from nosocomial MRSA in that it does not
generally belong to the major clonal groups of epidemic MRSA and
is susceptible to most non-beta-lactam antibiotics. In contrast,
nosocomial MRSA is generally multidrug-resistant.6,7 Although
infections caused by CA- and HA-MRSA are increasing worldwide
and there are several reports of their distributions in Iran,8 the
prevalence of MRSA in the western part of Iran remains uncertain
due to the lack of any large-scale studies on these strains.
The aims of the current study were to determine the SCCmec
and spa types, as well as the occurrence of the different resistance
genes, and also to correlate these with phenotypic antibiotic
susceptibility patterns, for CA- and HA-MRSA isolates in the
western region of Iran.
2. Materials and methods
2.1. Study population and S. aureus identiﬁcation
MRSA clinical isolates (n = 100), including 62 HA isolates
(recovered 48 h after hospital admission) and 38 potentially CA
isolates (recovered within 48 h of admission, or from those
admitted to the emergency ward with no information related to
admission date) were collected from six selected hospitals in the
west of Iran during June 2010 to June 2011 (http://www.cdcgov/
mrsa/healthcare/index.html).
All clinical isolates were identiﬁed as S. aureus by positive Gram
staining, the utilization of mannitol salt agar (Oxoid, Hampshire,
UK), and the production of coagulase.
2.2. Phenotypic identiﬁcation of MRSA
MRSA strains were identiﬁed by growth on Mueller–Hinton
agar (Oxoid, Hampshire, UK) including 6 mg/ml of oxacillin and 4%
NaCl.2.3. Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by disk agar
diffusion (DAD) method on Mueller–Hinton agar (HiMedia, India),
in accordance with the recommendations of the Clinical and
Laboratory Standards Institute (CLSI), using the following anti-
biotics: penicillin, gentamicin, tobramycin, amikacin, kanamycin,
clindamycin, tetracycline, erythromycin, ciproﬂoxacin, rifampin,
quinupristin–dalfopristin, linezolid, tigecycline, and imipenem.9
High-level resistance to gentamicin was evaluated using Etest
gentamicin strips (AB Biodisk, Solna, Sweden), as recommended by
the manufacturer. The minimum inhibitory concentration (MIC) of
vancomycin (from Sigma brand) was evaluated by a broth
microdilution method in accordance with the CLSI guidelines.9
In order to calculate the MIC50 and MIC90, the MICs of gentamicin
and vancomycin for each strain were sorted into ascending order.
The MIC50 was taken as the MIC that was the median value; the
MIC90 represented the concentration of antibiotic that would
inhibit 90% of the isolates tested. S. aureus ATCC 25923 was used for
quality control. All intermediate resistance phenotypes were
considered as resistant. Inducible resistance to clindamycin was
detected for those isolates that were susceptible to clindamycin
and resistant to erythromycin, by a double-disk diffusion test (D-
test), in accordance with the CLSI guidelines and previous
reports.9,10 Blunting of the inhibition zone around the clindamycin
disk was considered as positive for inducible clindamycin
resistance. S. aureus ATCC 29213 was used as the reference strain
for quality control purposes.
2.4. DNA extraction
The bacterial DNA extractions were performed using a modiﬁed
phenol-based DNA extraction method, as reported previously.11
2.5. PCR ampliﬁcation of different genes
All methicillin-resistant isolates were then examined for the
existence of mecA, femA, ermA, B, and C, blaZ, mupA, linA, msrA, and
AME, including aac(60)-aph(200), aph(30), ant(40), aph(200)-Ib, aph(200)-
Ic, and aph(200)-Id, by PCR with speciﬁc primers, as described
previously.10,12–20 PCR was performed in a ﬁnal volume of 25 ml
containing 1 PCR buffer, 2.5 mM MgCl2, 0.2 mM dNTPs, 15 mg/ml
template DNA, and 1.5 U Taq polymerase (Fermentas, Lithuania)
and the primer concentration as per a previous report.10,12–20 The
PCR protocol was carried out in accordance with previous
reports.10,12–20 Ampliﬁed products were analyzed by electropho-
resis on 1% agarose gel. DNA bands were observed by staining with
ethidium bromide and photographed under UV illumination.
Enterococcus faecalis strain JH2-2, which lacks AME genes, E.
faecalis strain 1070, which contains the aac(60)-Ie-aph(200), aph(30),
and ant(40) genes, and Enterococcus faecium strain 899, which
contains the aac(60)-Ie-aph(200), aph(200)-Id, aph(30), and ant(40)
genes, were used as controls.18 MRSA WBG525, which contains
mecA, femA, and blaZ, was used as control. Standard positive strains
for ermA–C, linA, msrA, mupA, aph(200)-Ib, and aph(200)-Ic were not
available in this study; therefore, in addition to checking the size of
the amplicon, negative strains were repeated twice for accuracy.
2.6. SCCmec and spa typing
A multiplex-PCR assay was performed for the typing of SCCmec
types and subtypes, as reported previously.21 Strains that were
non-typeable by the previous method were further characterized
using a combination of two SCCmec typing methods, as described
by Oliveira et al. in 2002 and Zhang et al. in 2005.13,22 MRSA
reference strains COL (SCCmec type I, ccr1), XU642 (EMRSA-16,
Table 1
Antimicrobial resistance patterns of HA- and CA-MRSA isolates
Antibiotics HA-MRSA
(n = 62), n (%)
CA-MRSA
(n = 38), n (%)
Total
(n = 100), n (%)
Penicillin 62 (100) 38 (100) 100 (100)
Oxacillin 62 (100) 38 (100) 100 (100)
Vancomycin 0 0 0
Clindamycin 18 (29.0) 9 (23.7) 27 (27)
Erythromycin 32 (51.6) 18 (47.4) 50 (50)
Gentamicin 12 (19.3) 6 (15.8) 18 (18)
Amikacin 12 (19.3) 5 (13.1) 17 (17)
Kanamycin 12 (19.3) 6 (15.8) 18 (18)
Tobramycin 12 (19.3) 6 (15.8) 18 (18)
Rifampin 11 (17.7) 3 (7.9) 14 (14)
Tetracycline 16 (25.8) 10 (26.3) 26 (26)
Quinupristin–dalfopristin 0 0 0
Linezolid 0 0 0
Tigecycline 1 (1.6) 0 1 (1)
Imipenem 3 (4.8) 0 3 (3)
MRSA, methicillin-resistant Staphylococcus aureus; HA, hospital-acquired; CA,
community-acquired.
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WBG9465 (EMRSA-15, SCCmec type IV, ccr2), and WIS (SCCmec
type V, ccrC)23 were used as controls.
spa typing was performed as described previously, and spa
types were assigned through the Ridom web server (http://
www.ridom.de/spaserver/) and analyzed by BURP (based upon
repeat pattern) algorithm.24 BURP parameters that excluded spa
types shorter than 5 repeats and grouped spa types if costs were 4
were adopted.25
2.7. Statistical analysis
Fisher’s exact test was employed to assess the correlation
between different antibiotic resistance, the relevant encoding
genes, SCCmec types, and spa types. In order to estimate the p-
value and its conﬁdence interval, the Monte Carlo method was
used. The data were analyzed using R software version 2.1.
3. Results
The distribution of MRSA isolates was assessed in the four
following provinces in the west of Iran: Ilam (26%), Hamadan
(25%), Lorestan (27%), and Kermanshah (22%). The samples
originated from wound (48%), blood (32%), urine (14%), sputum
(5%), and trachea (1%). Wound infections were considered as
wounds in patients with a trauma or injury to the skin or soft tissue
that was infected by S. aureus strains.Table 2
Distribution of different SCCmec types according to antibiotic resistance phenotype am
Antibiotic resistance phenotype CA-MRSA SCCmec types (n = 38) 
I III IVc IVd 
Penicillin (n = 100) 3 (7.9) 17 (44.7) 11 (28.9) 6 (16.7)
Oxacillin (n = 100) 3 (7.9) 17 (44.7) 11 (28.9) 6 (16.7)
Clindamycin (n = 27) 0 6 (66.7) 2 (5.3) 1 (11.1)
Erythromycin (n = 50) 3 (16.7) 7 (38.9) 3 (16.7) 4 (22.2)
Gentamicin (n = 18) 0 6 (100) 0 0 
Amikacin (n = 17) 0 5 (90) 1 (5.9) 0 
Kanamycin (n = 18) 0 6 (100) 0 0 
Tobramycin (n = 18) 0 6 (100) 0 0 
Rifampin (n = 14) 0 2 (50) 2 (50) 0 
Tetracycline (n = 26) 1 (10) 6 (60) 2 (20) 1 (10) 
Tigecycline (n = 1) 0 0 0 0 
Imipenem (n = 3) 0 0 0 0 
MRSA, methicillin-resistant Staphylococcus aureus; HA, hospital-acquired; CA, communIn total, 38% (38/100) of all isolates were recovered from
outpatients in the emergency department and classiﬁed as CA-
MRSA; 62% (62/100) were from different wards of selected
hospitals and were classiﬁed as HA-MRSA. Male surgery (30%),
female surgery (20%), female internal medicine (8%), and male
internal medicine (4%) were the most common wards for isolation
of HA-MRSA in this study. The distributions of mecA and femA
among MRSA isolates were 100% and 88%, respectively. All isolates
were susceptible to quinupristin–dalfopristin, linezolid, and
vancomycin (MIC ranges of 0.12–1 mg/ml; MIC50 0.25 mg/ml and
MIC90 1 mg/ml), but were resistant to penicillin (100%), oxacillin
(100%), erythromycin (50%), clindamycin (27%), ciproﬂoxacin
(23%), tetracycline (23%), gentamicin (18%), kanamycin (18%),
tobramycin (18%), amikacin (17%), rifampin (14%), tigecycline (1%),
and imipenem (3%).
As shown in Table 1, the antimicrobial resistance rates were
signiﬁcantly higher in HA-MRSA compared to CA-MRSA (29% vs.
23.7% for clindamycin, 51.6% vs. 47.4% for erythromycin, 19.3% vs.
13.1–15.8% for all aminoglycosides, and 17.7% vs. 7.9% for
rifampin; p  0.05); however, resistance rates to tigecycline were
similar among HA-MRSA and CA-MRSA (25.8% vs. 26.3%, respec-
tively). Also, resistance to tigecycline and imipenem was observed
only among HA-MRSA (1.6% and 4.8%, respectively).
SCCmec type III (45%), IVc (24%), and IVd (20%) were the most
prevalent types among MRSA isolates. The prevalences of SCCmec
types III (44.7% vs. 45.7%), IVd (16.7% vs. 22.6%), V (2.6% vs. 3.2%),
and I (8.1 vs. 7.9), but not of SCCmec type IVc (28.9% vs. 20.1%),
were lower in CA-MRSA isolates compared to HA-MRSA (Table 2).
A signiﬁcant difference was found in the distribution of SCCmec
type IVc between CA-MRSA and HA-MRSA (p  0.05), while the
differences in distribution of the other SCCmec types were not
signiﬁcant.
SCCmec type III was the most detected SCCmec type in Ilam,
Khorramabad, and Kermanshah city, with 73.1% (19/26), 40.7%
(11/27), and 36.7% (8/22), respectively, while SCCmec type IVd was
the most detected in Hamadan city, with 24% (9/25) (the
distribution of other SCCmec types among cities is given in the
Supplementary Material Table S1).
As shown in Table 3, spa typing of MRSA isolates identiﬁed 13
distinct spa types. BURP analysis clustered spa types into four
groups named A to D in this study. BURP group A included spa types
t12311, t021, and t037; BURP group B included spa types t1074 and
t1234; BURP group C included spa types t230 and t1149; and
ﬁnally BURP group D included spa types t230 and t11332. spa types
t701, t790, 1991, and t2651 were not assigned to any BURP group
and were identiﬁed as singletons. spa type t701 was the most
frequently identiﬁed genotype both in HA-MRSA and CA-MRSA
(30/100 MRSA isolates). spa types t12311, t021, and t037, which
were all assigned to BURP group A, were the other most frequentlyong CA- and HA-MRSA isolates
HA-MRSA SCCmec types (n = 62)
V I III IVc IVd IVd
 1 (2.6) 5 (8.1) 28 (45.7) 13 (20.1) 14 (22.6) 14 (22.6)
 1 (2.6) 5 (8.1) 28 (45.7) 13 (20.1) 14 (22.6) 14 (22.6)
 0 0 13 (20.1) 4 (22.2) 0 0
 1 (5.5) 5 (15.6) 18 (56.2) 14 (43.7) 1 (3.1) 1 (3.1)
0 0 10 (83.3) 1 (8.3) 0 0
0 0 9 (83.3) 1 (8.3) 0 0
0 0 10 (83.3) 1 (8.3) 0 0
0 0 10 (83.3) 1 (8.3) 0 0
0 0 6 (60) 3 (30) 1 (10) 1 (10)
0 0 12 (75) 3 (18.7) 0 0
0 0 0 1 (100) 0 0
0 0 1 (33.3) 1 (33.3) 0 0
ity-acquired.
Table 3
spa typing and BURP analysis for 100 MRSA
spa type Repeat ID (%) HA-MRSA (%) CA-MRSA (%) BURP group SCCmec types (%)
t701 11-10-21-17-34-24-34-22-25-25 30 16 14 Singleton III (11), IVd (11), IVc (5),V(1),I (2)
t12311 15-12-16-02-491-24 15 11 4 A III (12), IVc (2), V (1)
t021 15-12-16-02-16-02-25-17-24 11 6 5 A III (4), IVc (4), IVd(2), I (1)
t037 15-12-16-02-25-17-24 10 7 3 A III (7), IVc (2), I (1)
t10740 07-12-21-17-34-13-13-34-33-34 9 5 4 B IVc (4), III (3), IVd (1), V (1)
t790 26-23-13-23-31-29-17-25-17-25-16-28 5 3 2 Singleton III (2), I (3)
t436 04-21-12-41-20-17 4 3 1 D III (3), IVd (1)
t230 08-16-02-16-34 4 1 3 C III (1), IVc (2), IVd (2)
t11332 04-21-12-41-486-17-12-12-17 4 3 1 D IVd (2), IVc (2)
t1149 08-16-34-24-34-17-17 2 2 - C I (1),IVd (2)
t1234 07-23-12-12-34-34-34-33-34 2 2 - B IVd (1), IVc (1)
t1991 08-17 2 2 - Singleton IVc (2)
t2651 14-44-12-23-18-17 2 1 1 Singleton III (2)
BURP, based upon repeat pattern; MRSA, methicillin-resistant Staphylococcus aureus; HA, hospital-acquired; CA, community-acquired.
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and 10% of all MRSA strains, respectively. We report spa type
t12311 for the ﬁrst time from Iran and also in the world. The new
spa type t12311 was the most distributed in Ilam, with 46.7% (7/
15), and Lorestan, with 33.3% (5/15). spa type t12311 was
identiﬁed more frequently among HA-MRSA than CA-MRSA
(73.3% vs. 26.7%, respectively). Similarly, spa types t1149, t1234,
and t1991 were identiﬁed among HA-MRSA but not CA-MRSA.
SCCmec type IIIA was the most prevalent type found in all spa types
except for spa types t1149, t1234, and t1991. SCCmec types IVc,
IVd, and V were variably found among MRSA strains (Table 3 and
Supplementary Material Table S1).
Similar to other studies from Iran, some of the isolates belonged
to t037 and t790 SCCmec III, but most of the isolates were not in
agreement with other reports from Iran.26–28
All beta-lactam-resistant isolates harbored blaZ but not mupA
genes. Most erythromycin-resistant MRSA isolates had ermA and/
or ermC genes but not ermB. Three erythromycin-resistant isolates
had msrA. linA was detected in 16 isolates but only four
clindamycin-resistant isolates harbored this gene. The D-zone
was shown in two erythromycin-resistant and clindamycin-
sensitive MRSAs. The distribution of macrolide and lincosamine-
resistant genes among erythromycin- and clindamycin-resistant
isolates is shown in the Supplementary Material Table S1.Table 4






1 Blood Women, internal 8 t10740 
2 Sputum Women, internal 32 t12311 
3 Blood Women, internal 64 t12311 
4 Wound Men, internal 64 t12311 
5 Blood Men, internal 128 t12311 
6 Blood Emergency department 128 t12311 
7 Urine Men, surgery 256 t12311 
8 Blood Men, surgery 256 t037 
9 Blood Men, surgery 256 t701 
10 Blood Men, surgery 256 t037 
11 Wound Emergency department 256 t12311 
12 Wound Emergency department 256 t701 
13 Wound Emergency department 256 t12311 
14 Wound Emergency department 256 t12311 
15 Blood Women, internal 256 t12311 
16 Urine Women, internal 256 t12311 
17 Blood Emergency department 256 t037 
18 Blood Women, surgery 256 t11332 
AME, aminoglycoside modifying enzymes; MIC, minimum inhibitory concentration; MRegardless of gene combinations, the most prevalent AME gene
was aac(60)-1e-aph(200)-1a (77.8%), followed by aph(30)-IIIa (38.9%)
and ant(40)-1a (27.8%). Of aminoglycoside-resistant staphylococci,
83.3% (15/18) contained at least one AME gene. Three isolates that
were resistant to gentamicin (16.7%), kanamycin (16.7%), tobra-
mycin (16.7%), and amikacin (17.6%) did not harbor any of the AME
genes (Supplementary Material Table S1 and Table 4). As shown
in Table 4, the MICs of gentamicin in the isolates without any AME
genes showed that one isolate had a MIC of 8 mg/ml and two had a
MIC of 256 mg/ml. The coexistence of two or three AME genes
was detected in gentamicin-resistant isolates. Gentamicin MIC
ranged between 8 and >256 mg/ml. Both MIC50 and MIC90 of
gentamicin among gentamicin-resistant MRSA isolates were
>256 mg/ml. Fourteen out of 18 (77.8%) isolates had MIC 128–
256 mg/ml and were considered highly gentamicin-resistant
MRSA, among which 42.8% (6/14) harbored at least aac(60)-1e-
aph(200)-1a and 42.8% (6/14) harbored at least two or three AME
genes. Two highly gentamicin-resistant MRSA did not harbor any
AME genes. The majority of gentamicin-resistant MRSA (83.3%)
belonged to SCCmec type IIIA, and 66.7% had a MIC of 256 mg/ml.
spa types t12311 (12/18) and t037 (3/18) that belonged to BURP
group A were the most distributed among gentamicin-resistant













B IVc   
A III + + 
A III +  
A III +  +
A III +  +
A III  + 
A III   
A III +  
Singleton III +  
A III + + 
A III   
Singleton III +  
A III + + +
A IVc + + 
A III + + +
A V + + +
A III +  
A III +  
RSA, methicillin-resistant Staphylococcus aureus; BURP, based upon repeat pattern.
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MRSA is one of the major causes of nosocomial and community-
acquired infections throughout the world. A recent systematic
review and recent meta-analyses show that the rate of MRSA in
Iran is high and varies between 20.4% and 90% in different areas of
the country.29 To date, different studies have been focused on the
distribution and phenotypic and genotypic characteristics of
antimicrobial resistance among MRSA isolates in Iran.11,14,20,30–
33 However, this is the ﬁrst large-scale study of antimicrobial
susceptibility patterns, different encoding resistance genes, and
SCCmec and spa types in MRSA isolates in the west of Iran.
Like other studies from Iran,8,34–36 most isolates were sensitive
to vancomycin (100%), quinupristin–dalfopristin (100%), linezolid
(100%), tigecycline (99%), and imipenem (97%). These results
showed that these antibiotics, especially vancomycin, can still be
used to treat different staphylococcal infections in Iran, although
some cases of resistance have been reported from this country.26,37
In this study, 88% of all mecA-positive isolates harbored the
femA regulating gene, thus conﬁrming previous data showing that
the presence of femA confers high-level resistance to methicillin in
S. aureus.38,39
Surprisingly, the rate of resistance to aminoglycosides among
MRSA isolates found in the present study was lower than that
reported in other studies. This event could be explained by the low
number of MRSA isolated from the different provinces of the west
of Iran, or by the low level of aminoglycoside prescription during
the treatment of MRSA infections. The ﬁrst reason is probably
closest to the reality and is in accordance with an analysis of
antimicrobial susceptibility done in Ilam Province (data not
shown) that showed nearly 44.4% (n = 12/27) of MRSA isolates
to be resistant to gentamicin. This resistance proﬁle in Ilam
Province is also fairly consistent with other reports from Iran.40
Although resistance to aminoglycoside drugs has emerged
worldwide, these drugs alone and in combination with other
antibiotics have important effects in the treatment of staphylo-
coccal infections.20,40–42
Mounting evidence indicates a key role of aac(60)-1e-aph(200)-1a
and aph(30)-IIIa in resistance to gentamicin, tobramycin, kanamy-
cin, and amikacin in staphylococci. In accordance with these
studies, aac(60)-1e-aph(200)-1a and aph(30)-IIIa genes were distrib-
uted widely among aminoglycoside-resistant MRSA isolates in
western Iran, with prevalences of 77.8% and 38.9%, respectively,
regardless of their gene combinations.40–42
However, only three out 18 gentamicin-, kanamycin-, and
tobramycin-resistant MRSA and three out of 17 amikacin-resistant
MRSA had no AME-encoding genes. Also, no AME-encoding genes
were found among the aminoglycoside-susceptible MRSA isolates,
which may be another possible explanation for the low percentages
of resistance against aminoglycosides in this study. In agreement
with previous studies,21,42,18 aac(60)-1e-aph(200)-1a alone and in
combination with aph(30)-IIIa and ant(40)-1a was the most prevalent
AME gene among the highly gentamicin-resistant MRSAs.38,42,43
Additional epidemiological information was provided by spa
genotyping of MRSA isolates. The majority (66%; 66/100 MRSA) of
HA-MRSA and CA-MRSA isolates were assigned to spa type t701
(identiﬁed in 30% of MRSA isolates) and spa types t12311, t021, and
t037 (all assigned to BURP group A, identiﬁed in the other 36% of
MRSA strains), thus suggesting that the increase in MRSA isolation
in western Iran is attributable to the spread of a limited number of
genotypes.
The majority of aminoglycoside-resistant isolates belonged to
HA-MRSA SCCmec type III spa type t12311 and t037 that in case of
t037 and t790 was in consistent with other reports from Iran. We
report spa type t12311 for the ﬁrst time.26–28 SCCmec type III
contained different resistance genes including AME-encodinggenes that were located on transposons and plasmids integrated
into the SCCmec element.13,20 On the other hand, these results
show that resistance to aminoglycosides is more common among
nosocomial infections.
Another resistance mechanism that was evaluated in this study
was macrolide–lincosamide resistance among MRSA isolates. In
accordance with a previous report from Iran,14 resistance rates to
erythromycin and clindamycin were 50% and 27%, respectively. The
rates of constitutive and inducible resistance against macrolides
were 26% and 2%, respectively, which are lower than those reported
in other studies.14,44,45 Unlike other studies in which ermA had the
most important role in macrolide resistance,46,47 this study showed
ermC to be the most prevalent gene among macrolide-resistant
MRSA in the west of Iran and that ermB does not play an important
role in macrolide-resistant MRSA, which is contradictory to previous
reports from Iran.14Similar to other studies, no ermB gene was found
among macrolide-resistant MRSA isolates. In similar studies, the
prevalence rate of ermB was seen in just a few erythromycin-
resistant staphylococci.45 The results showed that resistance to
erythromycin was due to ermC among MRSA isolates in Iran.
We found a correlation between SCCmec types III–spa types
t701/t12311 among HA-MRSA in the west of Iran (p  0.05).
Distribution patterns of SCCmec types and spa types in CA-MRSA
and HA-MRSA in this study were not consistent with the previously
deﬁned SCCmec types, because SCCmec types IV and V, associated
with CA-MRSA, have now been introduced into the hospital setting
and cause nosocomial infections. Also, nosocomial SCCmec type III
has spread from the hospital to the community and vice versa.
SCCmec type IIIA–spa types t701/t12311 was the predominant type
among all CA- and HA-MRSA isolates and showed variable
antimicrobial resistance phenotypes and genotypes. Other than
SCCmec type III–spa types t701/t12311 that was conﬁrmed to
harbor different resistance genes, no other correlations between
other SCCmec types and antimicrobial susceptibilities were found.
The MRSA isolates with the SCCmec type III–spa types t701/t112311
genotype were obtained from patients in different provinces during
the study period, suggesting that cross-infection was a factor in the
maintenance of this MRSA SCCmec type III– spa types t701/t12311
in hospitals located in the west of Iran. Similar to this study,
studies from Kuwait, Saudi Arabia, Thailand, and some Asian
countries have shown MRSA with the SCCmec type III genotype
to be common among the hospitals of those countries.8,46–50
Finally, it appears that spa typing in combination with SCCmec
typing provides useful information for determining the epidemio-
logic relationship of a group of MRSA isolates recovered in the
hospitaland/or community inthe westof Iran.Also, the results of this
studyshowed thatresistanceagainstmanyantibioticshas decreased
in the west of Iran and that these could therefore be very promising
antimicrobial agents for the treatment of MRSA infections.14,41
To determine the exact antimicrobial susceptibility proﬁles and
their encoding resistance genes among MRSA isolates in the
community and hospital settings in the west of Iran, comprehensive
research and a large-scale study including more data on phenotypic
and genotypic characteristics of MRSA are needed.
Acknowledgements
This work forms part of a Master’s thesis and two MD student
theses that have been supported by Ilam University of Medical
Sciences and Health Services grants (numbers 919012/88, 919012/
188 and 921007/45). We thank all of the staff of the Microbiology
Laboratory and School of Medicine of Ilam University of Medical
Sciences for their help and considerations.
Ethical approval: This work was approved by the Ethics
Committee of Ilam University of Medical Sciences.
Conﬂict of interest: None.
S. Mohammadi et al. / International Journal of Infectious Diseases 25 (2014) 152–158 157Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2014.02.018.
References
1. Wang L, Archer GL. Roles of CcrA and CcrB in excision and integration of
staphylococcal cassette chromosome mec, a Staphylococcus aureus genomic
island. J Bacteriol 2010;192:3204–12.
2. Wisplinghoff H, Ewertz B, Wisplinghoff S, Stefanik D, Plum G, Perdreau-Reming-
ton F, et al. Molecular evolution of methicillin-resistant Staphylococcus aureus in
the metropolitan area of Cologne, Germany, from 1984 to 1998. J Clin Microbiol
2005;43:5445–51.
3. Wang WY, Chiueh TS, Sun JR, Tsao SM, Lu JJ. Molecular typing and phenotype
characterization of methicillin-resistant Staphylococcus aureus isolates from
blood in Taiwan. PLoS One 2012;7:e30394.
4. Valsesia G, Rossi M, Bertschy S, Pfyffer GE. Emergence of SCCmec type IV and
SCCmec type V methicillin-resistant Staphylococcus aureus containing the Pan-
ton–Valentine leukocidin genes in a large academic teaching hospital in central
Switzerland: external invaders or persisting circulators? J Clin Microbiol
2010;48:720–7.
5. Labrou M, Michail G, Ntokou E, Pittaras TE, Pournaras S, Tsakris A. Activity of
oxacillin versus that of vancomycin against oxacillin-susceptible mecA-positive
Staphylococcus aureus clinical isolates evaluated by population analyses, time-
kill assays, and a murine thigh infection model. Antimicrob Agents Chemother
2012;56:3388–91.
6. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al.
Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and
harmonisation of typing methods. Int J Antimicrob Agents 2012;39:273–82.
7. Wang JL, Wang JT, Chen SY, Chen YC, Chang SC. Distribution of staphylococcal
cassette chromosome mec types and correlation with comorbidity and infection
type in patients with MRSA bacteremia. PLoS One 2010;5:e9489.
8. Fatholahzadeh B, Emaneini M, Gilbert G, Udo E, Aligholi M, Modarressi MH, et al.
Staphylococcal cassette chromosome mec (SCCmec) analysis and antimicrobial
susceptibility patterns of methicillin-resistant Staphylococcus aureus (MRSA)
isolates in Tehran, Iran. Microb Drug Resist 2008;14:217–20.
9. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. Twenty-ﬁrst informational supplement. M100-
S21. Wayne, PA: CLSI; 2011.
10. Shahsavan S, Emaneini M, Noorazar Khoshgnab B, Khoramian B, Asadollahi P,
Aligholi M, et al. A high prevalence of mupirocin and macrolide resistance
determinant among Staphylococcus aureus strains isolated from burnt patients.
Burns 2012;38:378–82.
11. Japoni A, Jamalidoust M, Farshad S, Ziyaeyan M, Alborzi A, Japoni S, et al.
Characterization of SCCmec types and antibacterial susceptibility patterns of
methicillin-resistant Staphylococcus aureus in Southern Iran. Jpn J Infect Dis
2011;64:28–33.
12. Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes
for Staphylococcus aureus enterotoxins, exfoliative toxins, toxic shock
syndrome toxin 1, and methicillin resistance. J Clin Microbiol 2000;38:
1032–1035.
13. Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identiﬁcation of
structural types and variants of the mec element in methicillin-resistant
Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:2155–61.
14. Emaneini M, Eslampour MA, Sedaghat H, Aligholi M, Jabalameli F, Shahsavan S,
et al. Characterization of phenotypic and genotypic inducible macrolide resis-
tance in staphylococci in Tehran, Iran. J Chemother 2009;21:595–7.
15. Martineau F, Picard FJ, Lansac N, Menard C, Roy PH, Ouellette M, et al. Correla-
tion between the resistance genotype determined by multiplex PCR assays and
the antibiotic susceptibility patterns of Staphylococcus aureus and Staphylococ-
cus epidermidis. Antimicrob Agents Chemother 2000;44:231–8.
16. Udo EE, Jacob LE, Mathew B. Genetic analysis of methicillin-resistant Staphylo-
coccus aureus expressing high- and low-level mupirocin resistance. J Med
Microbiol 2001;50:909–15.
17. Aminia AA, Chungc Ch, Jahanshiric F, Wongc CB, Poylingc B, Hematian A, et al.
Circulation and transmission of methicillin-resistant Staphylococcus aureus
among college students in Malaysia (cell phones as reservoir). Asian Biomed
2012;6:659–73.
18. Zarrilli R, Tripodi MF, Di Popolo A, Fortunato R, Bagattini M, Crispino M, et al.
Molecular epidemiology of high-level aminoglycoside-resistant enterococci
isolated from patients in a university hospital in southern Italy. J Antimicrob
Chemother 2005;56:827–35.
19. Vakulenko SB, Donabedian SM, Voskresenskiy AM, Zervos MJ, Lerner SA, Chow
JW. Multiplex PCR for detection of aminoglycoside resistance genes in entero-
cocci. Antimicrob Agents Chemother 2003;47:1423–6.
20. Fatholahzadeh B, Emaneini M, Feizabadi MM, Sedaghat H, Aligholi M,
Taherikalani M, et al. Characterisation of genes encoding aminoglycoside-
modifying enzymes among meticillin-resistant Staphylococcus aureus
isolated from two hospitals in Tehran, Iran. Int J Antimicrob Agents 2009;33:
264–265.
21. Zhang K, McClure JA, Conly JM. Enhanced multiplex PCR assay for typing of
staphylococcal cassette chromosome mec types I to V in methicillin-resistant
Staphylococcus aureus. Mol Cell Probes 2012;26:218–21.22. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multiplex PCR assay for
characterization and concomitant subtyping of staphylococcal cassette chro-
mosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin
Microbiol 2005;43:5026–33.
23. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V
staphylococcal cassette chromosome mec driven by a novel cassette chromo-
some recombinase, ccrC. Antimicrob Agents Chemother 2004;48:2637–51.
24. Harmsen D, Claus H, Witte W, Rothganger J, Turnwald D, Vogel U. Typing of
methicillin-resistant Staphylococcus aureus in a university hospital setting by
using novel software for spa repeat determination and database management. J
Clin Microbiol 2003;41:5442–8.
25. Mellmann A, Weniger T, Berssenbrugge C, Rothganger J, Sammeth M, Stoye J,
et al. Based Upon Repeat Pattern (BURP): an algorithm to characterize the long-
term evolution of Staphylococcus aureus populations based on spa polymor-
phisms. BMC Microbiol 2007;7:98.
26. Azimian A, Havaei SA, Fazeli H, Naderi M, Ghazvini K, Samiee SM, et al. Genetic
characterization of a vancomycin-resistant Staphylococcus aureus isolate from
the respiratory tract of a patient in a university hospital in northeastern Iran. J
Clin Microbiol 2012;50:3581–5.
27. Japoni-Nejad A, Rezazadeh M, Kazemian H, Fardmousavi N, van Belkum A,
Ghaznavi-Rad E. Molecular characterization of the ﬁrst community-acquired
methicillin-resistant Staphylococcus aureus strains from Central Iran. Int J Infect
Dis 2013;17:e949–54.
28. Emaneini M, Khoramrooz SS, Taherikalani M, Jabalameli F, Aligholi M. Molecu-
lar characterization of Staphylococcus aureus isolated from children with ade-
noid hypertrophy: emergence of new spa types t7685 and t7692. Int J Pediatr
Otorhinolaryngol 2011;75:1446–9.
29. Askari E, Soleymani F, Arianpoor A, Tabatabai SM, Amini A, Naderinasab M.
Epidemiology of mecA-methicillin resistant Staphylococcus aureus (MRSA) in
Iran: a systematic review and meta-analysis. Iranian Journal of Basic Medical
Sciences 2012;15:1010–9.
30. Abbasi-Montazeri E, Khosravi AD, Feizabadi MM, Goodarzi H, Khoramrooz SS,
Mirzaii M, et al. The prevalence of methicillin resistant Staphylococcus aureus
(MRSA) isolates with high-level mupirocin resistance from patients and per-
sonnel in a burn center. Burns 2013;39:650–4.
31. Askarian M, Zeinalzadeh A, Japoni A, Alborzi A, Memish ZA. Prevalence of nasal
carriage of methicillin-resistant Staphylococcus aureus and its antibiotic sus-
ceptibility pattern in healthcare workers at Namazi Hospital, Shiraz, Iran. Int J
Infect Dis 2009;13:e241–7.
32. Fatholahzadeh B, Emaneini M, Aligholi M, Gilbert G, Taherikalani M, Jonaidi N,
et al. Molecular characterization of methicillin-resistant Staphylococcus aureus
clones from a teaching hospital in Tehran. Jpn J Infect Dis 2009;62:309–11.
33. Ghasemian R, Najaﬁ N, Makhlough A, Khademloo M. Frequency of nasal
carriage of Staphylococcus aureus and its antimicrobial resistance pattern in
patients on hemodialysis. Iranian Journal of Kidney Diseases 2010;4:218–22.
34. Haeili M, Ghodousi A, Nomanpour B, Omrani M, Feizabadi MM. Drug resistance
patterns of bacteria isolated from patients with nosocomial pneumonia at
Tehran hospitals during 2009–2011. J Infect Dev Ctries 2013;7:312–7.
35. Motamedifar M, Hassanzadeh P, Ghafari N. Relative frequency of staphylococ-
cal carriage and antibiotic sensitivity of isolated staphylococci in hemodialysis
patients in Shiraz, Iran. Med Princ Pract 2010;19:379–83.
36. Shahraz F, Dadkhah H, Khaksar R, Mahmoudzadeh M, Hosseini H, Kamran M,
et al. Analysis of antibiotic resistance patterns and detection of mecA gene in
Staphylococcus aureus isolated from packaged hamburger. Meat Sci
2012;90:759–63.
37. Emaneini M, Aligholi M, Hashemi FB, Jabalameli F, Shahsavan S, Dabiri H, et al.
Isolation of vancomycin-resistant Staphylococcus aureus in a teaching hospital
in Tehran. J Hosp Infect 2007;66:92–3.
38. Li X, Xiong Y, Fan X, Feng P, Tang H, Zhou T. The role of femA regulating gene on
methicillin-resistant Staphylococcus aureus clinical isolates. Med Mal Infect
2012;42:218–25.
39. Maidhof H, Reinicke B, Blumel P, Berger-Bachi B, Labischinski H. femA, which
encodes a factor essential for expression of methicillin resistance, affects
glycine content of peptidoglycan in methicillin-resistant and methicillin-sus-
ceptible Staphylococcus aureus strains. J Bacteriol 1991;173:3507–13.
40. Yadegar A, Sattari M, Mozafari NA, Goudarzi GR. Prevalence of the genes
encoding aminoglycoside-modifying enzymes and methicillin resistance
among clinical isolates of Staphylococcus aureus in Tehran, Iran. Microb Drug
Resist 2009;15:109–13.
41. Emaneini M, Taherikalani M, Eslampour MA, Sedaghat H, Aligholi M, Jabalameli
F, et al. Phenotypic and genotypic evaluation of aminoglycoside resistance in
clinical isolates of staphylococci in Tehran, Iran. Microb Drug Resist
2009;15:129–32.
42. Udo EE, Dashti AA. Detection of genes encoding aminoglycoside-modifying
enzymes in staphylococci by polymerase chain reaction and dot blot hybrid-
ization. Int J Antimicrob Agents 2000;13:273–9.
43. Ida T, Okamoto R, Shimauchi C, Okubo T, Kuga A, Inoue M. Identiﬁcation of
aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of
methicillin-resistant Staphylococcus aureus in Japan. J Clin Microbiol
2001;39:3115–21.
44. Adaleti R, Nakipoglu Y, Ceran N, Tasdemir C, Kaya F, Tasdemir S. Prevalence of
phenotypic resistance of Staphylococcus aureus isolates to macrolide, lincosa-
mide, streptogramin B, ketolid and linezolid antibiotics in Turkey. Braz J Infect
Dis 2010;14:11–4.
45. Appalaraju B, Jayakumar S. Inducible clindamycin resistance in Staphylococcus
aureus isolated from clinical samples. J Commun Dis 2010;42:263–8.
S. Mohammadi et al. / International Journal of Infectious Diseases 25 (2014) 152–15815846. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. Distribution
of genes encoding resistance to macrolides, lincosamides, and streptogramins
among staphylococci. Antimicrob Agents Chemother 1999;43:1062–6.
47. Schmitz FJ, Sadurski R, Kray A, Boos M, Geisel R, Kohrer K, et al. Prevalence of
macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium
isolates from 24 European university hospitals. J Antimicrob Chemother
2000;45:891–4.
48. Udo EE, Panigrahi D, Jamsheer AE. Molecular typing of methicillin-resistant
Staphylococcus aureus isolated in a Bahrain hospital. Med Princ Pract 2008;17:
308–314.49. Chongtrakool P, Ito T, Ma XX, Kondo Y, Trakulsomboon S, Tiensasitorn C, et al.
Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-re-
sistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal
for a new nomenclature for SCCmec elements. Antimicrob Agents Chemother
2006;50:1001–12.
50. Cirlan M, Saad M, Coman G, Bilal NE, Elbashier AM, Kreft D, et al. International
spread of major clones of methicillin resistant Staphylococcus aureus: nosoco-
mial endemicity of multi locus sequence type 239 in Saudi Arabia and Romania.
Infect Genet Evol 2005;5:335–9.
